Difference between revisions of "Team:AQA Unesp"

 
(147 intermediate revisions by the same user not shown)
Line 12: Line 12:
 
overflow:hidden;
 
overflow:hidden;
 
background-size: cover;
 
background-size: cover;
−
min-height: 100%;
+
padding: 5% 0;
−
display:inline-flex;
+
−
align-items: center;
+
−
justify-content: center;
+
 
}
 
}
  
Line 23: Line 20:
 
}
 
}
  
−
.insubiota-text {  font:72pt caviardreams, sans-serif; text-align: center; color:white }
+
.insubiota-text {  font:12em caviardreams, sans-serif; text-align: center; color:white }
  
−
.insubiota-subtext {  font:2em caviardreams, sans-serif; text-align: center; color:white }
+
.insubiota-subtext {  font:2em caviardreams, sans-serif; text-align: center; color:white; }
 +
 
 +
#titleinsubiota {padding: 10% 0;}
 +
 
 +
#abstract { font:5em caviardreams, sans-serif; text-align: center; color: white; font-weight:bold; padding-top: 2%}
 +
 
 +
#gold-award { float:left; }
  
 
</style>
 
</style>
Line 32: Line 35:
 
<div class="foto-grande">
 
<div class="foto-grande">
  
 +
<div id="titleinsubiota">
 +
<div style="width:950px; margin: 0 auto">
 +
 +
<img src="https://static.igem.org/mediawiki/2017/e/ec/Gold-award-aqaunesp.png" width="200px" id="gold-award">
 
<div class="insubiota-text">INSUBIOTA</div>
 
<div class="insubiota-text">INSUBIOTA</div>
 
<div class="insubiota-subtext">treating diabetes with genetically engineered probiotic</div>
 
<div class="insubiota-subtext">treating diabetes with genetically engineered probiotic</div>
  
 +
</div>
 
</div>
 
</div>
  
 +
</div>
  
 +
<div style="width:100%; margin: 0 auto; background-color: #44558f">
  
 +
<div id="abstract">ABSTRACT</div>
  
 +
<div style="max-width:1000px; font-size:1.5em; margin: 2% auto; line-height:1.5; text-align:justify; color: white; padding-top:2%; padding-bottom: 2%">
 +
Our project was inspired on the alarming and increasing number of diabetic people, especially diabetes mellitus type 1 patients, who are insulin dependent. The lack of less invasive treatments has motivated us to develop a new treatment based on the probiotic bacteria <i>Lactococcus lactis</i>, that was engineered to produce a single-chain analog insulin in human diabetic’s microbiota. The bacteria will be able to produce the insulin associated with a secretion signal sequence and cell-penetrating peptides, to ensure its uptake. Moreover, the synthesis of the insulin will be controlled by the natural bacteria system of catabolite repression with regulation by a small RNA. At the presence of glucose, the insulin gene expression will be activated, and then, it will be ready to be secreted and absorbed, reaching the blood and performing its biological function. Also, in order to contain the release of our engineered probiotic to the environment, we built a kill switch based on light exposure that uses the CRISPR/Cas9 system to destroy essential genes for the bacterial survival. The final product could be a fermented milk or a lyophilized that could be easily ingested by patients.
  
−
<!--
+
</div>
−
<div id="logo_grande"><img src="https://static.igem.org/mediawiki/2017/6/6a/T--AQA_Unesp--logoInsubiota_index.png"></div>
+
</div>
−
<div id="subtitle_index">A genetically engineered probiotic bacteria that can produce insulin at diabetic people's microbiota</div>
+
 
−
<div class="faixa"></div>
+
<div style="text-align:center">
−
<iframe width="1200" height="675" src="https://www.youtube.com/embed/1g0_meAvO_U?rel=0&amp;controls=0&amp;showinfo=0" frameborder="0" allowfullscreen style="text-align:center"></iframe>
+
<video width="1000" controls>
−
-->
+
<source src="https://static.igem.org/mediawiki/2017/a/a7/Aqaunesp-video-insubiota.mp4" type="video/mp4">
 +
</video>
 +
</div>
 +
 
 +
<style>
 +
#buttons { max-width:1100px; margin:3% auto; display:table}
 +
 
 +
.botao-link {
 +
position: relative;
 +
width: 150px;
 +
float:left;
 +
margin:5px;
 +
}
 +
 
 +
 
 +
.image {
 +
  display: block;
 +
  width: 150px;
 +
  height: 150px;
 +
}
 +
 
 +
.overlay {
 +
  position: absolute;
 +
  top: 0;
 +
  bottom: 0;
 +
  left: 0;
 +
  right: 0;
 +
  height: 100%;
 +
  width: 100%;
 +
  opacity: 0;
 +
  transition: .5s ease;
 +
  background-color: #008CBA;
 +
border-radius:50%;
 +
}
 +
 
 +
#projectdesc {background-color: RGB(255,208,91)}
 +
#design {background-color: RGB(159,159,226)}
 +
#hpp {background-color: RGB(50,74,94)}
 +
#team {background-color: RGB(255,76,58)}
 +
 
 +
.botao-link:hover .overlay {
 +
  opacity: 1;
 +
}
 +
 
 +
.text {
 +
  color: white;
 +
  font-size: 20px;
 +
  position: absolute;
 +
  top: 50%;
 +
  left: 50%;
 +
  transform: translate(-50%, -50%);
 +
  -ms-transform: translate(-50%, -50%);
 +
}
 +
 
 +
</style>
 +
 
 +
<div id="buttons">
 +
 
 +
<div class="botao-link">
 +
<a href="https://2017.igem.org/Team:AQA_Unesp/Description">
 +
<img src="https://static.igem.org/mediawiki/2017/f/f5/Aqaunesp-projectdescription-icon.png" class="image">
 +
<div class="overlay" id="projectdesc">
 +
<div class="text">project description</div>
 +
</div>
 +
</a>
 +
</div>
 +
 
 +
<div class="botao-link">
 +
<a href="https://2017.igem.org/Team:AQA_Unesp/Applied_Design">
 +
<img src="https://static.igem.org/mediawiki/2017/c/cd/AQAUnesp-design-icon.png" class="image">
 +
<div class="overlay" id="design">
 +
<div class="text">design</div>
 +
</div>
 +
</a>
 +
</div>
 +
 
 +
<div class="botao-link">
 +
<a href="https://2017.igem.org/Team:AQA_Unesp/Results">
 +
<img src="https://static.igem.org/mediawiki/2017/7/7c/Aqaunesp-results-icon.png" class="image">
 +
<div class="overlay" id="projectdesc">
 +
<div class="text">results</div>
 +
</div>
 +
</a>
 +
</div>
 +
 
 +
<div class="botao-link">
 +
<a href="https://2017.igem.org/Team:AQA_Unesp/HP/Silver">
 +
<img src="https://static.igem.org/mediawiki/2017/0/0a/AQAUnesp-hp-icon.png" class="image">
 +
<div class="overlay" id="hpp">
 +
<div class="text">human practices</div>
 +
</div>
 +
</a>
 +
</div>
 +
 
 +
<div class="botao-link">
 +
<a href="https://2017.igem.org/Team:AQA_Unesp/Team">
 +
<img src="https://static.igem.org/mediawiki/2017/b/bd/AQAUnesp-team-icon.png" class="image">
 +
<div class="overlay" id="team">
 +
<div class="text">team</div>
 +
</div>
 +
</a>
 +
</div>
 +
 
 +
</div>
  
 
</body>
 
</body>
 
</html>
 
</html>
 
{{AQA_Unesp_btm}}
 
{{AQA_Unesp_btm}}

Latest revision as of 18:13, 15 December 2017



iGEM AQA_Unesp

INSUBIOTA
treating diabetes with genetically engineered probiotic
ABSTRACT
Our project was inspired on the alarming and increasing number of diabetic people, especially diabetes mellitus type 1 patients, who are insulin dependent. The lack of less invasive treatments has motivated us to develop a new treatment based on the probiotic bacteria Lactococcus lactis, that was engineered to produce a single-chain analog insulin in human diabetic’s microbiota. The bacteria will be able to produce the insulin associated with a secretion signal sequence and cell-penetrating peptides, to ensure its uptake. Moreover, the synthesis of the insulin will be controlled by the natural bacteria system of catabolite repression with regulation by a small RNA. At the presence of glucose, the insulin gene expression will be activated, and then, it will be ready to be secreted and absorbed, reaching the blood and performing its biological function. Also, in order to contain the release of our engineered probiotic to the environment, we built a kill switch based on light exposure that uses the CRISPR/Cas9 system to destroy essential genes for the bacterial survival. The final product could be a fermented milk or a lyophilized that could be easily ingested by patients.
Team: AQA_Unesp